Palvella Therapeutics (NASDAQ:PVLA) said it reported positive top-line results from its phase III SELVA study evaluating QTORIN 3.9% rapamycin in hydrogel as a once-daily topical treatment for microcystic lymphatic malformations (mLM), a rare, serious, and chronically debilitating genetic disease with no FDA-approved therapies. Management highlighted that QTORIN rapamycin met the study’s primary endpoint, the key […]